Effects and mechanisms of action of Yiqi wenyang huwei decoction in improving bronchial asthma in rats
- VernacularTitle:益气温阳护卫汤对支气管哮喘大鼠的改善作用及机制
- Author:
Yunqing YANG
1
;
Jianyu XIE
2
;
Wei TANG
3
;
Chao YE
3
;
Qiangqiang YU
3
;
Peng SUN
3
;
Yuping YANG
3
;
Jianwei YU
3
Author Information
1. College of Clinical Medicine，Jiangxi University of Chinese Medicine，Nanchang 330004，China
2. College of Traditional Chinese Medicine，Jiangxi University of Chinese Medicine，Nanchang 330004，China
3. Dept. of Pulmonary Diseases，the Affiliated Hospital of Jiangxi University of Chinese Medicine，Nanchang 330006，China
- Publication Type:Journal Article
- Keywords:
Yiqi wenyang huwei decoction;
bronchial asthma;
airway inflammation;
airway remodeling;
TLR4/MyD88/NF-κB
- From:
China Pharmacy
2026;37(10):1264-1271
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effects and potential mechanism of Yiqi wenyang huwei decoction （YQWY） in improving airway inflammation and remodeling in rats with bronchial asthma （BA） based on the Toll-like receptor 4 （TLR4）/myeloid differentiation primary response protein 88 （MyD88）/nuclear factor-κB （NF-κB） signaling pathway. METHODS Male SD rats were randomly divided into the normal group， the model group， the dexamethasone group （positive control， 0.5 mg/kg）， and YQWY low-， medium- and high-dose groups （5， 10， 20 g/kg， calculated by the crude drug）， with 8 rats in each group. Except for the normal group， rats in all other groups were sensitized twice with ovalbumin combined with aerosol challenge to establish a BA model. From day 14 to day 34 of the experiment， the rats in each group were administered the corresponding drug solution or normal saline intragastrically， once a day， 1 hour before aerosol challenge. At 24 hours after the final aerosol challenge， asthma symptom scores were assessed， serum levels of immunoglobulin E （IgE） were measured， and the levels of inflammatory cytokines （interleukin-4， interleukin-5， interleukin-13 and tumor necrosis factor-α） and the numbers of inflammatory cells （white blood cell， eosinophil， neutrophil， lymphocyte， monocyte and basophil） in bronchoalveolar lavage fluid were determined. Pathological changes in lung tissue were observed. The mRNA expressions of TLR4， MyD88 and NF-κB， as well as the protein expressions of TLR4， MyD88， NF-κB p65 and phosphorylated NF-κB p65 in lung tissue， were detected. RESULTS Compared with the model group， the pathological changes， such as inflammatory cell infiltration， abnormal deposition of collagen fibers， and goblet cell hyperplasia in the lung tissue of rats in each drug group， were alleviated to varying degrees. The asthma symptom scores （except for the YQWY low-dose group）， the levels of IgE and inflammatory cytokines （except for interleukin-5 in the YQWY medium-dose group）， the number of inflammatory cells （except for monocyte and basophil in the YQWY low-dose group）， the mRNA expression of TLR4， MyD88 and NF-κB， as well as the protein expressions of TLR4， MyD88， NF-κB p65 and phosphorylated NF-κB p65 （except for MyD88 and NF-κB p65 proteins in the YQWY low-dose group as detected by Western blo t） were all significantly reduced or down-regulated （ P ＜0.05 or P ＜0.01）. CONCLUSIONS YQWY can alleviate asthma-like manifestations in BA rats and improve their airway inflammation and remodeling； these effects may be related to the formula’s inhibition of the abnormal activation of the TLR4/MyD88/NF-κB signaling pathway.
